Home blood draws and symptom scores sent to the rheumatologist between visits
TL;DR Flarepost is a subscription for people with diagnosed rheumatoid arthritis. Each month a phlebotomist draws blood at home for CRP and ESR, the patient fills a short symptom score on the phone, and the treating rheumatologist gets a one-page trend report. Rheumatology clinics enrol patients, and patients pay monthly.
About 0.34% of Indians have rheumatoid arthritis, according to the national COPCORD-BJD survey[1]. Care is slow to start. In a Karnataka study of 2,141 patients across 17 centres, the median wait from first symptoms to a rheumatologist was 18 months, and 52% reported paying out of pocket[2]. And once treated, many still run hot. In a Pune study of 120 older patients, 63.3% had high disease activity and only 34.2% were on disease-modifying drugs[3]. Treatment is meant to be adjusted if it is not working within three to six months[4], which needs regular measurement that patients far from the clinic rarely get.
What it does, in regulatory terms: monitoring and reporting only. Flarepost collects lab results and patient-reported scores and shows them to the treating rheumatologist, who makes every treatment decision. It does not diagnose or recommend drugs. If the report calculates a composite disease score, check with a regulatory adviser whether that counts as medical device software under CDSCO's 2026 guidance[5].
Here's how it works. A partner NABL-accredited lab collects blood at home once a month or on the doctor's schedule. The patient answers a validated symptom questionnaire in the app, in English or a regional language. The rheumatologist gets a trend chart before the next visit and an alert when inflammation markers and symptoms rise together.
I reframed the seed, which pitched home biomarker tracking with AI insights for "chronic inflammation" in general. What does a healthy person do with a rising CRP? Nothing useful, so I narrowed it to a diagnosed disease where these markers are already part of care, and left AI out until the data justifies it.
The patient or family pays a monthly fee covering home collection, tests and the report. A single CRP test with free home collection costs ₹399 at one national lab chain[6], so a bundle has a visible price anchor. Rheumatology clinics are the channel and not the payer - they enrol patients and get better data between visits. Hospital rheumatology departments could buy it as a service for their own patients later.
Home sample collection is now routine in Indian cities, and lab chains compete on price, as the ₹399 CRP listing shows[6]. CDSCO's final guidance on medical device software in July 2026 tells founders where the line sits for clinical software[5]. The DPDP rules set out consent duties for health data.
There's no public figure for spending on rheumatoid arthritis monitoring in India. The narrow signal is the gap in control - 63.3% high disease activity in one clinic cohort[3] and an 18-month median delay to specialist care[2]. Applying the 0.34% prevalence[1] to India's population suggests a few million patients, but most are not under a rheumatologist, so the reachable market is far smaller.
National lab chains offer home collection for single tests[6] but no disease-specific report for the treating doctor. Hospital rheumatology units track patients at visits on paper or in their own records. I found no Indian company running monthly RA monitoring for clinics, though my search was limited. The gap is the link between home testing and the rheumatologist's next decision.
| Difficulty | Moderate (37/100) |
| Starting capital | ₹35–70 L |
| Time to launch | 4–6 months |
The software is simple. The hard parts are getting rheumatologists to read one more report, keeping patients drawing blood every month once they feel better, and staying clearly on the monitoring side of the medical device line. Nothing here needs new science, thankfully.
Partly. The monitoring itself needs no licence, but the software and labs need care.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
AI must not suggest a flare diagnosis or a drug change. The rheumatologist makes every treatment decision. Keep the software to collecting and showing data, which also keeps the regulatory question simple.
Want to work out the AI layer for Flarepost? Talk to Yash →
I think this is a good fit for a founder with clinic relationships and operations experience in lab services. If you want a consumer wellness app then look elsewhere. First prove two things - that ten rheumatologists will enrol patients and that 60% of those patients are still testing after three months.
Plan for roughly ₹35–70 L for software, phlebotomy staff and early operations.
Use NABL-accredited labs, follow the DPDP Act, and get an opinion on whether score calculations make your software a medical device.
Yes. Check local device software and health data rules first. My advice is to run a small paid pilot with a few real customers before you commit the full budget.
The free Flarepost validation kit has the line-by-line capital breakdown, the effort scoring, the software and data-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for patients and rheumatologists, and 5 assumptions to test. Download the kit →
Thinking about building Flarepost or something close to it? The make-or-break work is getting rheumatologists to act on the report and keeping patients testing once they feel well, and that's the kind of thing I help founders work through. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.